Studies Nieuws Nieuwsbrief Over ons Archief
Zoek beschikbare studies

Studieoverzicht

Study name: Intracranial Sacituzumab govitecan (SG) + bevacizumab

Histology NSCLC
Tumor stage Stage III - IV
Host / recruiting site 1 Antoni van Leeuwenhoek Enrollment Recruiting
Host / recruiting site 2 MUMC+ Enrollment Recruiting
Host / recruiting site 3 UMC Groningen Enrollment Planned
Therapy line Later line (≥2L)
Design

Multicentre, single arm phase II study.
Intervention

Sacituzumab govitecan (SG) + bevacizumab
Key outcome parameters

To evaluate the BM ORR at 12 weeks of SG and bevacizumab measured with the Response Assessment in Neuro-Oncology (RANO)-BM criteria51
Key inclusion criteria
  • Pathology proven metastatic non-squamous NSCLC
  • BM not in eloquent area (all patients have at least to be discussed with a neurologist, and preferably they are discussed in the local neuro-oncology MDT).
  • Maximum BM size 2 cm in longest diameter (for each BM).
Key exclusion criteria
  • Leptomeningeal metastasis (based on MRI or CSF cytology, if strong suspicion despite negative MRI, CSF analysis should be done)
Contact information